DKK3

DUBLIN, Dec. 13, 2023 /PRNewswire/ -- The "MTG201 + nivolumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about MTG201 + nivolumab for malignant pleural mesothelioma (MPM) in the seven major markets. A detailed picture of the MTG201 + nivolumab for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the MTG201 + nivolumab for MPM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MTG201 + nivolumab market forecast analysis for MPM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in MPM. Drug Summary MTG201 is novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. The drug candidate leverages the company's proprietary adenoviral vector technology platform to deliver the reduced expression in immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene is markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. At the same time, increased expression of the REIC/Dkk3 gene in normal cell components in tumor tissue promotes antitumor immunity by activating dendritic cells and natural killer (NK) cells while suppressing immune-suppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSC). Based on these novel dual mechanisms, MTG201 is believed to be well-positioned to work synergistically with checkpoint inhibitors such as nivolumab. The Phase II trial (NCT04013334), conducted at the Baylor College of Medicine in Houston, Texas, is an open-label, single-arm study designed to assess the efficacy, safety, and tolerability of intratumoral administration of MTG201 in combination with nivolumab. The trial enrolled up to twelve patients with malignant mesothelioma who have failed front-line systemic platin-based chemotherapy. The study's primary objective is to assess the efficacy of the treatment combination, with the primary endpoint being objective response rate (ORR). MTG201 + nivolumab Analytical Perspective In-depth MTG201 + nivolumab Market Assessment This report provides a detailed market assessment of MTG201 + nivolumab for malignant pleural mesothelioma (MPM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032. MTG201 + nivolumab Clinical Assessment The report provides the clinical trials information of MTG201 + nivolumab for MPM covering trial interventions, trial conditions, trial status, start and completion dates. Report Highlights In the coming years, the market scenario for malignant pleural mesothelioma (MPM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MTG201 + nivolumab dominance. Other emerging products for MPM are expected to give tough market competition to MTG201 + nivolumab and launch of late-stage emerging therapies in the near future will significantly impact the market. A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MTG201 + nivolumab in MPM. This in-depth analysis of the forecasted sales data of MTG201 + nivolumab from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MTG201 + nivolumab in MPM. Key Topics Covered: 1. Report Introduction 2. MTG201 + nivolumab Overview in MPM 2.1. Product Detail 2.2. Clinical Development 2.2.1. Clinical studies 2.2.2. Clinical trials information 2.2.3. Safety and efficacy 2.3. Other Developmental Activities 2.4. Product Profile 3. Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging Therapies) 5. MTG201 + nivolumab Market Assessment 5.1. Market Outlook of MTG201 + nivolumab in MPM 5.2. 7MM Analysis 5.2.1. Market Size of MTG201 + nivolumab in the 7MM for MPM 5.3. Country-wise Market Analysis 5.3.1. Market Size of MTG201 + nivolumab in the United States for MPM 5.3.2. Market Size of MTG201 + nivolumab in Germany for MPM 5.3.3. Market Size of MTG201 + nivolumab in France for MPM 5.3.4. Market Size of MTG201 + nivolumab in Italy for MPM 5.3.5. Market Size of MTG201 + nivolumab in Spain for MPM 5.3.6. Market Size of MTG201 + nivolumab in the United Kingdom for MPM 5.3.7. Market Size of MTG201 + nivolumab in Japan for MPM 6. SWOT Analysis 7. Analysts' Views For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

Stablix Therapeutics launched with a $63 million Series A financing round that will be used to develop the company’s and advance a portfolio of protein stabilizers towards the clinic. New York-based Stablix’s TPS platform, dubbed RESTORED, “generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity,” according to the company announcement. Stablix will initially aim the platform to develop programs that treat rare diseases, cancer, and immunological disorders. With the RESTORED platform, Stablix said it’s possible to inhibit the ubiquitin-proteasome system in a target-selective manner to treat some of these diseases. “Stablix possesses a first-in-category platform that can restore protein stability and function in a target-selective manner,” Carlo Rizzuto, a partner at Versant and acting Chief Executive Officer of Stablix said in a statement. “We are very pleased to launch this company to address this important therapeutic white space for numerous devastating diseases.” The company pointed to cystic fibrosis as a disease that could benefit from its approach. Stablix said mutations in the CFTR gene produce a functional protein that is subject to excessive ubiquitination. This can lead to rapid degradation through the proteasome. Excess ubiquitination is also a hallmark of some cancers, where E3 ubiquitin ligases are “frequently upregulated or amplified.” This drives the degradation of tumor suppressor proteins, the company added. The Series A financing round was led by Versant Ventures, the founding investor of Stablix. NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities also contributed. Stablix wasn’t the only company to announced funds from a Series A financing round this morning. Texas-based Stellanova Therapeutics, a resident company at JLABS @ TMC, closed a $15.5 million Series A financing round. Funds will be used to support the development of antibody drugs and a discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, which can render resistant cancers treatable. Stellanova aims to advance its lead antibody asset into the clinic. Stellanova is focused on targeting pro-tumorigenic effects enabled by the activity of carcinoma-associated fibroblasts (known as CAFs) in the tumor microenvironment. These CAFs play significant roles in promoting cancer growth and metastasis. They spur angiogenesis, suppress anti-tumor immunity, and foster chemoresistance. Stellanova’s lead antibody candidate is designed to neutralize DKK3, a factor secreted by CAFs that acts on neighboring cancer cells and immune cells to promote tumor progression and therapy resistance. Rosa Hwang, co-founder of Stellanova, said the company’s lead antibody shows robust anti-tumor activity, alone or together with immune therapy, in highly refractory preclinical models of the pancreas and triple negative breast cancer. The Series A financing round was led by Sporos Bioventures, LLC. Belgium-based Amyl Therapeutics raised €18.3 million ($22.3 million) in Series A funding. The company will use funds from the round to advance the discovery and development of preclinical therapeutic candidates that can target multiple misfolded proteins implicated in both progressive peripheral and rare neurodegenerative diseases. The company’s amyloid fibrils specific technology platform dubbed ClariTY was developed for the treatment of all forms of Amyloidosis, which can be seen in diseases such as Alzheimer’s and Parkinson’s. Therapeutic assets based on the ClariTY platform are designed to prevent the further accumulation of these amyloid aggregates and clear existing aggregates from the peripheral organs and the brain. Also, they are designed to block further “cell-to-cell spread of misfolded proteins.” The company believes these therapies may offer a breakthrough approach to treat protein misfolding diseases. The financing round was composed of an €8.6 million equity investment led by Belgium-based Noshaq, with participation from Merieux Participations, Sambrinvest, and other private investors. Additionally, a non-dilutive funding of €9.7 million was made by the DG06, a Belgium-based policy-design and implementing body.

~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently bind to and systemically deliver therapeutic levels of multiple types of nucleic acid payloads to cells in vitro and tumors in vivo ~ ~ GMABD31N combined with a RIG-I ligand 3pRNA (GMABD31N/3pRNA) efficiently targets and delivers a known RIG-I agonist to tumors in vivo and effectively prevents tumor growth in a mouse model of melanoma, comparable to anti-CTLA-4 ~ NEW HAVEN, Conn., April 10, 2021 (GLOBE NEWSWIRE) -- Gennao Bio, a privately-held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced a late-breaking poster detailing preclinical results for its proprietary, non-viral gene monoclonal antibody (GMAB) nucleic acid delivery system. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021. The GMAB technology platform, exclusively licensed from Yale University, utilizes a proprietary, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of multiple types of nucleic acids, including synthetic RNA (ribonucleic acid) messenger RNA, small interfering RNA, deoxyribonucleic acids, antisense oligonucleotides and gene editing molecules. The preclinical data presented in the poster show the utility of the monoclonal antibody 3E10-D31N (GMABD31N) to deliver nucleic acids to cells in vitro and to tumors in vivo. This antibody, a modified version of 3E10, forms non-covalent complexes with RNAs and can mediate highly specific delivery broadly into tumors via intravenous injection by targeting the nucleoside transporter ENT2. ENT2 is highly expressed in multiple tumor types as well as skeletal and cardiac muscle. Studies completed with labeled RNAs and messenger RNAs expressing a green fluorescent protein reporter gene show tumor specific delivery and functional expression by imaging, with minimal delivery to healthy tissues. Cell culture studies show antibody-mediated delivery of a series of retinoic acid-inducible gene I (RIG-I) ligands, including hairpin RNAs and synthetic double-stranded RNA (poly(I:C)), resulting in robust RIG-I stimulation and induction of type-1 interferon signaling. Most importantly, when using a mouse B16 melanoma tumor model, substantial tumor growth suppression was observed upon intravenous injection of GMABD31N non-covalently bound to 3pRNA, an 89-nucleotide, single-stranded RNA. In this study, the tumor suppression observed was comparable to the tumor suppression that was observed using anti-CTLA-4. “The preclinical results presented today highlight the ability of GMABD31N to systemically deliver immunostimulatory RNAs in a targeted, non-invasive manner,” said Peter M. Glazer, M.D., Ph.D., Chair of the Department of Therapeutic Radiology, Professor of Genetics and Robert E. Hunter Professor of Therapeutic Radiology at the Yale School of Medicine. “This approach has the potential to offer new and significant treatment advantages over current delivery methods that are associated with systemic toxicity or rely on direct intra-tumoral injection, which is therapeutically sub-optimal, especially for metastatic disease. I look forward to working with Gennao Bio on the continued development of the GMAB platform to develop effective therapeutics for the treatment of oncology indications, as well as monogenic skeletal and cardiac muscle diseases.” The full abstract and poster presentation can be accessed on the AACR annual meeting website, , through June 21, 2021. About Gennao Bio Gennao Bio is a privately-held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (GMAB) platform technology. GMAB technology utilizes a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. Gennao Bio is developing this delivery system with an initial focus on oncology and monogenic skeletal muscle diseases. Investor and Media Contact: Gennao BioChris Duke732-735-0330cduke@gennaobio.com Source: Gennao Bio